<DOC>
	<DOCNO>NCT02941848</DOCNO>
	<brief_summary>The purpose study evaluate Pharmacokinetic Properties Safety administration HCP1306 tablet Co-administration HGP0816 tablet , HGP1404 tablet healthy adult .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Safety HCP1306 Co-administration HGP0816 , HGP1404 Healthy Male Volunteers</brief_title>
	<detailed_description>A Randomized , Open-Label , Two-way Crossover , Single-Dose Study Compare Pharmacokinetic Properties Safety administration HCP1306 tablet Co-administration HGP0816 tablet , HGP1404 tablet healthy adult</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>[ Inclusion criterion ] 1 . Healthy adult 19 50 age screening . 2 . 18.5 ≤ Body mass index ( BMI ) &lt; 25 . ※ BMS ( kg/m2 ) = body weight ( kg ) / [ height ( ) 2 ] 3 . Body weight ≥ 55 kg men ≥ 50 kg woman . 4 . Individual consider responsible physician eligible subject base result hematology test , blood chemistry test , immunoserology test , urinalysis , electrocardiogram ( ECG ) perform accord characteristic drug ( include clinically significant ( NCS ) abnormality ) . 5 . Women must negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test screen negative predose urine βhCG test time point define protocol must applicable one following . Postmenopausal ( spontaneous menstruation least 2 year ) Surgical sterilization ( sterilized hysterectomy , bilateral ovariectomy tubal ligation , method ) A male partner sterilize prior screen ( document azoospermia follow vasectomy ) man subject 's partner . The subject must agree use adequate method contraception continuously properly period time least 14 day prior first dose least 28 day last dose investigational product . Adequate method contraception include abstinence physical barrier method ( e.g. , condom , diaphragm , cervical cap ) contraceptive device pill contain hormone may drugdrug interaction investigational product use study period , principle . 6 . Sexually active male subject female partner childbearing potential must agree avoid pregnancy ( condom , etc . ) study maintain adequate method contraception donate sperm study 28 day last dose investigational product ( method contraception necessary male subject female partner sterile ) . 7 . After receive understanding sufficient explanation study , individual must voluntarily decide participate study provide write informed consent comply study instruction . [ Exclusion criterion ] 1 . Evidence history clinically significant disease hepatobiliary system , kidney , nervous system , psychiatric system , respiratory system , endocrine system ( thyroid dysfunction , etc . ) , hematooncology , cardiovascular system , immune system , musculoskeletal system ( myopathy , etc. ) . 2 . History gastrointestinal disorder ( e.g. , Crohn 's disease , ulcerative colitis ) surgery ( except simple typhlotomy hernia repair ) may affect absorption investigational product . 3 . Hypersensitivity reactions component investigational product excipients drug class . 4 . Hereditary disorder galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 5 . Vital sign measure sit position least 5 minute rest follow : systolic blood pressure ( SBP ) &gt; 150 mmHg &lt; 90 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg &lt; 50 mmHg . 6 . Screening clinical laboratory test result follow : Blood total bilirubin level &gt; 1.5 x upper limit normal ( ULN ) Blood aspartate aminotransferase ( AST , also know serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT , also know serum glutamate pyruvate transaminase [ SGPT ] ) &gt; 1.25 x ULN Blood urea nitrogen ( BUN ) &gt; 25.0 mg/dL creatinine &gt; 1.4 mg/dL Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 calculate Modification Diet Renal Disease ( MDRD ) equation ※ eGFR ( mL/min/1.73m2 ) = 175 x [ serum creatinine ( mg/dL ) ] 1.154 x [ age ( year ) ] 0.203 ( X 0.742 , female ) Blood Creatinine Phosphokinase ( CK ) &gt; 2 x ULN 7 . History significant drug abuse within 1 year screen positive urine drug test result . 8 . Administration drug within 30 day investigational product administration expect may affect metabolism investigational product . 9 . Administration follow drug within relevant period , except local agent without significant systemic absorption hormonal contraceptive . Ethical ( ETC ) drug within 14 day first investigational product administration Overthecounter ( OTC ) drug include health food vitamin preparation within 7 day first investigational product administration Drugs administer via depot injection implantation ( except contraceptive ) within 30 day first investigational product administration 10 . Significant alcohol dependency within 1 year screening , continuous drinking within 6 month screen ( &gt; 210 g/week ) , unable refrain drinking study period start 2 day prior first investigational product administration . 11 . Continuous caffeine intake ( e.g. , coffee &gt; 5 cups/day , tea &gt; 1250 cc/day , cola &gt; 1250 cc/day ) unable refrain caffeine intake study period start 2 day prior first investigational product administration . 12 . Continuous smoking ( &gt; 10 cigarettes/day ) unable refrain smoking study period start 2 day prior first investigational product administration . 13 . Intake grapefruit food contain grapefruit within 7 day prior first investigational product administration . 14 . Participation another clinical trial ( include bioequivalence study ) administration another investigational product within 60 day prior investigational product administration study ( 3 month biologics ; prolong period time may apply half life take account ) . 15 . Whole blood donation within 60 day apheresis donation within 30 day prior investigational product administration . 16 . Pregnant lactating woman . 17 . Subject consider investigator inappropriate study participation due reason .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>